Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 294 articles: HTML format

Single Articles

July 2021
1. DANOVARO-HOLLIDAY MC, Kretsinger K, Gacic-Dobo M
   Measuring and ensuring routine childhood vaccination coverage.
   Lancet. 2021 Jul 14. pii: S0140-6736(21)01228.
   PubMed    
   
   
   
2. CAUCHEMEZ S, Bosetti P, Kiem CT, Mouro V, et al
   Education and mental health: good reasons to vaccinate children.
   Lancet. 2021 Jul 14. pii: S0140-6736(21)01453.
   PubMed    
   
   
   
3. CAUSEY K, Fullman N, Sorensen RJD, Galles NC, et al
   Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study.
   Lancet. 2021 Jul 14. pii: S0140-6736(21)01337.
   PubMed     Abstract available
   
   
   
4. 
   Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.
   Lancet. 2021 Jul 14. pii: S0140-6736(21)00984.
   PubMed     Abstract available
   
   
   
5. THE LANCET
   COVID-19 in Latin America-emergency and opportunity.
   Lancet. 2021;398:93.
   PubMed    
   
   
   
6. TANRIOVER MD, Doganay HL, Akova M, Guner HR, et al
   Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
   Lancet. 2021 Jul 8. pii: S0140-6736(21)01429.
   PubMed     Abstract available
   
   
   June 2021
7. SMITH MJ
   What constitutes success in the roll-out of COVID-19 vaccines?
   Lancet. 2021 Jun 25. pii: S0140-6736(21)01244.
   PubMed    
   
   
   
8. DUARTE-SALLES T, Prieto-Alhambra D
   Heterologous vaccine regimens against COVID-19.
   Lancet. 2021 Jun 25. pii: S0140-6736(21)01442.
   PubMed    
   
   
   
9. BOROBIA AM, Carcas AJ, Perez-Olmeda M, Castano L, et al
   Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
   Lancet. 2021 Jun 25. pii: S0140-6736(21)01420.
   PubMed     Abstract available
   
   
   
10. THE LANCET
    Protecting refugees during the COVID-19 pandemic.
    Lancet. 2021;397:2309.
    PubMed    
    
    
    
11. ABECASSIS A
    Five priorities for universal COVID-19 vaccination.
    Lancet. 2021 Jun 17. pii: S0140-6736(21)01371.
    PubMed    
    
    
    
12. SHEIKH A, McMenamin J, Taylor B, Robertson C, et al
    SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
    Lancet. 2021 Jun 14. pii: S0140-6736(21)01358.
    PubMed    
    
    
    
13. GAYTHORPE KAM, Toor J, Echeverria-Londono S, Li X, et al
    Vaccines can save children with non-preventable diseases - Authors' reply.
    Lancet. 2021;397:2251.
    PubMed    
    
    
    
14. SAHA S, Saha SK
    Vaccines can save children with non-preventable diseases.
    Lancet. 2021;397:2250.
    PubMed    
    
    
    
15. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    COVID-19 vaccine efficacy data: solid enough to delay second dose? - Authors' reply.
    Lancet. 2021;397:2249-2250.
    PubMed    
    
    
    
16. ROBERTSON JFR, Sewell HF
    COVID-19 vaccine efficacy data: solid enough to delay second dose?
    Lancet. 2021;397:2248-2249.
    PubMed    
    
    
    
17. VOYSEY M, Pollard AJ
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.
    Lancet. 2021;397:2248.
    PubMed    
    
    
    
18. MCQUADE ETR, Platts-Mills JA
    ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates.
    Lancet. 2021;397:2247-2248.
    PubMed    
    
    
    
19. NASSER A, Zakham F
    A strategy for SARS-CoV-2 vaccination in Yemen.
    Lancet. 2021;397:2247.
    PubMed    
    
    
    
20. GUETL K, Gary T, Raggam RB, Schmid J, et al
    SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban.
    Lancet. 2021 Jun 11. pii: S0140-6736(21)01238.
    PubMed    
    
    
    
21. BOLLYKY TJ, Murray CJL, Reiner RC Jr
    Epidemiology, not geopolitics, should guide COVID-19 vaccine donations.
    Lancet. 2021 Jun 8. pii: S0140-6736(21)01323.
    PubMed    
    
    
    
22. KUMAR A, Bernasconi V, Manak M, de Almeida Aranha AP, et al
    The CEPI centralised laboratory network: supporting COVID-19 vaccine development.
    Lancet. 2021;397:2148-2149.
    PubMed    
    
    
    
23. WALL EC, Wu M, Harvey R, Kelly G, et al
    Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01290.
    PubMed    
    
    
    
24. NNAJI CA, Ndwandwe D, Lesosky M, Mahomed H, et al
    Tackling missed opportunities for vaccination in a new era of immunisation.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01226.
    PubMed    
    
    
    
25. KOSAKA M, Hashimoto T, Ozaki A, Tanimoto T, et al
    Delayed COVID-19 vaccine roll-out in Japan.
    Lancet. 2021 Jun 2. pii: S0140-6736(21)01220.
    PubMed    
    
    
    
26. FORMAN R, Jit M, Mossialos E
    Divergent vaccination policies could fuel mistrust and hesitancy.
    Lancet. 2021 Jun 1. pii: S0140-6736(21)01106.
    PubMed    
    
    
    May 2021
27. MAKONI M
    Africa's need for more COVID-19 clinical trials.
    Lancet. 2021;397:2037.
    PubMed    
    
    
    
28. JAWAD NK, Taweeleh LA, Elharake JA, Khamis N, et al
    Refugee access to COVID-19 vaccines in Lebanon.
    Lancet. 2021;397:1884.
    PubMed    
    
    
    
29. ZAROCOSTAS J
    What next for a COVID-19 intellectual property waiver?
    Lancet. 2021;397:1871-1872.
    PubMed    
    
    
    
30. LOYO ESL, Gonzalez MJ, Esparza J
    Venezuela is collapsing without COVID-19 vaccines.
    Lancet. 2021;397:1806.
    PubMed    
    
    
    
31. WATSON SI
    Global COVID-19 vaccine roll-out: time to randomise vaccine allocation?
    Lancet. 2021;397:1804-1805.
    PubMed    
    
    
    
32. TORRES I, Lopez-Cevallos D, Artaza O, Profeta B, et al
    Vaccine scarcity in LMICs is a failure of global solidarity and multilateral instruments.
    Lancet. 2021;397:1804.
    PubMed    
    
    
    
33. HOUSTON AR, Murthy S
    Canada is no global health leader on COVID-19 vaccine equity.
    Lancet. 2021;397:1803.
    PubMed    
    
    
    
34. HOLT E
    Serbia begins paying citizens to receive a COVID-19 vaccine.
    Lancet. 2021;397:1793.
    PubMed    
    
    
    
35. GENC K
    COVID-19 in Turkey: a nation on edge.
    Lancet. 2021;397:1794-1796.
    PubMed    
    
    
    
36. JHA P, Jamison DT, Watkins DA, Bell J, et al
    A global compact to counter vaccine nationalism.
    Lancet. 2021 May 14. pii: S0140-6736(21)01105.
    PubMed    
    
    
    
37. KUPPALLI K, Gala P, Cherabuddi K, Kalantri SP, et al
    India's COVID-19 crisis: a call for international action.
    Lancet. 2021 May 14. pii: S0140-6736(21)01121.
    PubMed    
    
    
    
38. SHAW RH, Stuart A, Greenland M, Liu X, et al
    Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.
    Lancet. 2021 May 12. pii: S0140-6736(21)01115.
    PubMed    
    
    
    
39. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV
    Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply.
    Lancet. 2021 May 12. pii: S0140-6736(21)00894.
    PubMed    
    
    
    
40. MOORTHY V, Binka F
    R21/Matrix-M: a second malaria vaccine?
    Lancet. 2021 May 5. pii: S0140-6736(21)01065.
    PubMed    
    
    
    
41. DATOO MS, Natama MH, Some A, Traore O, et al
    Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.
    Lancet. 2021 May 5. pii: S0140-6736(21)00943.
    PubMed     Abstract available
    
    
    
42. HAAS EJ, Angulo FJ, McLaughlin JM, Anis E, et al
    Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Lancet. 2021 May 5. pii: S0140-6736(21)00947.
    PubMed     Abstract available
    
    
    
43. LESHEM E, Wilder-Smith A
    COVID-19 vaccine impact in Israel and a way out of the pandemic.
    Lancet. 2021 May 5. pii: S0140-6736(21)01018.
    PubMed    
    
    
    
44. BHUYAN A
    Experts criticise India's complacency over COVID-19.
    Lancet. 2021;397:1611-1612.
    PubMed    
    
    
    April 2021
45. BURKI T
    Statelessness in the COVID-19 pandemic.
    Lancet. 2021;397:1529-1530.
    PubMed    
    
    
    
46. THE LANCET
    2021: the beginning of a new era of immunisations?
    Lancet. 2021;397:1519.
    PubMed    
    
    
    
47. HALL VJ, Foulkes S, Saei A, Andrews N, et al
    COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00790.
    PubMed     Abstract available
    
    
    
48. LESHEM E, Lopman BA
    Population immunity and vaccine protection against infection.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00870.
    PubMed    
    
    
    
49. DEAN N
    Hospital admissions due to COVID-19 in Scotland after one dose of vaccine.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00765.
    PubMed    
    
    
    
50. VASILEIOU E, Simpson CR, Shi T, Kerr S, et al
    Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study.
    Lancet. 2021 Apr 23. pii: S0140-6736(21)00677.
    PubMed     Abstract available
    
    
    
51. KHAN MS, Ali SAM, Adelaine A, Karan A, et al
    Rethinking vaccine hesitancy among minority groups.
    Lancet. 2021 Apr 21. pii: S0140-6736(21)00938.
    PubMed    
    
    
    
52. ALVES L
    Brazilian ICUs short of drugs and beds amid COVID-19 surge.
    Lancet. 2021;397:1431-1432.
    PubMed    
    
    
    
53. BAYAS A, Menacher M, Christ M, Behrens L, et al
    Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00872.
    PubMed    
    
    
    
54. MUSTER V, Gary T, Raggam RB, WOlfler A, et al
    Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00871.
    PubMed    
    
    
    
55. MFINANGA SG, Mnyambwa NP, Minja DT, Ntinginya NE, et al
    Tanzania's position on the COVID-19 pandemic.
    Lancet. 2021 Apr 14. pii: S0140-6736(21)00678.
    PubMed    
    
    
    
56. CAPUA I, Giaquinto C
    The unsung virtue of thermostability.
    Lancet. 2021;397:1346.
    PubMed    
    
    
    
57. ALI SN, Hanif W, Patel K, Khunti K, et al
    Ramadan and COVID-19 vaccine hesitancy-a call for action.
    Lancet. 2021 Apr 7. pii: S0140-6736(21)00779.
    PubMed    
    
    
    
58. D'SOUZA RS, Wolfe I
    COVID-19 vaccines in high-risk ethnic groups.
    Lancet. 2021 Apr 1. pii: S0140-6736(21)00624.
    PubMed    
    
    
    March 2021
59. EMARY KRW, Golubchik T, Aley PK, Ariani CV, et al
    Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00628.
    PubMed     Abstract available
    
    
    
60. OSTERGAARD SD, Schmidt M, Horvath-Puho E, Thomsen RW, et al
    Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00762.
    PubMed    
    
    
    
61. SANDERS RW, de Jong MD
    Pandemic moves and countermoves: vaccines and viral variants.
    Lancet. 2021 Mar 30. pii: S0140-6736(21)00730.
    PubMed    
    
    
    
62. MYLAN S, Hardman C
    COVID-19, cults, and the anti-vax movement.
    Lancet. 2021;397:1181.
    PubMed    
    
    
    
63. USHER AD
    Uncertainties over EU COVID-19 vaccine sharing scheme.
    Lancet. 2021;397:1171.
    PubMed    
    
    
    
64. KLUGE H, McKee M
    COVID-19 vaccines for the European region: an unprecedented challenge.
    Lancet. 2021 Mar 25. pii: S0140-6736(21)00709.
    PubMed    
    
    
    
65. 
    Human rights and fair access to COVID-19 vaccines: the International AIDS Society-Lancet Commission on Health and Human Rights.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00708.
    PubMed    
    
    
    
66. CHANDAN JS, Chandan JK
    Considering gender-based violence in vaccine prioritisation strategies.
    Lancet. 2021 Mar 24. pii: S0140-6736(21)00532.
    PubMed    
    
    
    
67. KRISTIANSEN PA, Page M, Bernasconi V, Mattiuzzo G, et al
    WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
    Lancet. 2021 Mar 23. pii: S0140-6736(21)00527.
    PubMed    
    
    
    
68. KARIM SSA
    Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00468.
    PubMed    
    
    
    
69. MUNDT AP
    Assessing government responsibility for COVID-19 deaths.
    Lancet. 2021 Mar 22. pii: S0140-6736(21)00529.
    PubMed    
    
    
    
70. SAAH AJ, Munoz N
    Control vaccine formulation - Authors' reply.
    Lancet. 2021;397:1062.
    PubMed    
    
    
    
71. DOSHI P, Hong K, Jefferson T, Jones M, et al
    Control vaccine formulation.
    Lancet. 2021;397:1061-1062.
    PubMed    
    
    
    
72. JAFFE S
    Biden's first legislative victory: $1.9 trillion for COVID-19.
    Lancet. 2021;397:1047-1048.
    PubMed    
    
    
    
73. BOZORGMEHR K, Jahn R, Stuckler D, McKee M, et al
    Free licensing of vaccines to end the COVID-19 crisis.
    Lancet. 2021 Mar 18. pii: S0140-6736(21)00467.
    PubMed    
    
    
    
74. KRIEGER N, Waterman PD, Chen JT, Testa C, et al
    Missing again: US racial and ethnic data for COVID-19 vaccination.
    Lancet. 2021 Mar 17. pii: S0140-6736(21)00465.
    PubMed    
    
    
    
75. HOLT E
    Countries split from EU on COVID-19 vaccines.
    Lancet. 2021;397:958.
    PubMed    
    
    
    
76. THE LANCET
    Access to COVID-19 vaccines: looking beyond COVAX.
    Lancet. 2021;397:941.
    PubMed    
    
    
    
77. STEINBERG J, Thomas A, Iravani A
    (18)Fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.
    Lancet. 2021 Mar 8. pii: S0140-6736(21)00464.
    PubMed    
    
    
    
78. SAMARASEKERA U
    Robin Shattock: novel vaccine developer.
    Lancet. 2021;397:870.
    PubMed    
    
    
    
79. HUNG IFN, Poland GA
    Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.
    Lancet. 2021;397:854-855.
    PubMed    
    
    
    
80. VIJAYASINGHAM L, Bischof E, Wolfe J
    Sex-disaggregated data in COVID-19 vaccine trials.
    Lancet. 2021 Mar 5. pii: S0140-6736(21)00384.
    PubMed    
    
    
    February 2021
81. BATNIJI R
    Historical evidence to inform COVID-19 vaccine mandates.
    Lancet. 2021;397:791.
    PubMed    
    
    
    
82. CHAUVIN L
    Peruvian COVID-19 vaccine scandal spreads.
    Lancet. 2021;397:783.
    PubMed    
    
    
    
83. ZAROCOSTAS J
    New WTO leader faces COVID-19 challenges.
    Lancet. 2021;397:782.
    PubMed    
    
    
    
84. PRENDECKI M, Clarke C, Brown J, Cox A, et al
    Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00502.
    PubMed    
    
    
    
85. MANISTY C, Otter AD, Treibel TA, McKnight A, et al
    Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
    Lancet. 2021 Feb 25. pii: S0140-6736(21)00501.
    PubMed    
    
    
    
86. 
    Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
    Lancet. 2021 Feb 24. pii: S0140-6736(21)00372.
    PubMed    
    
    
    
87. SIVA N
    Severe mental illness: reassessing COVID-19 vaccine priorities.
    Lancet. 2021;397:657.
    PubMed    
    
    
    
88. HYDE R
    von der Leyen admits to COVID-19 vaccine failures.
    Lancet. 2021;397:655-656.
    PubMed    
    
    
    
89. VOYSEY M, Costa Clemens SA, Madhi SA, Weckx LY, et al
    Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00432.
    PubMed     Abstract available
    
    
    
90. SISA I, Noblecilla E, Orozco F
    Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00357.
    PubMed    
    
    
    
91. ROBERTSON JFR, Sewell HF, Stewart M
    Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
    Lancet. 2021 Feb 19. pii: S0140-6736(21)00455.
    PubMed    
    
    
    
92. AMIT S, Regev-Yochay G, Afek A, Kreiss Y, et al
    Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
    Lancet. 2021 Feb 18. pii: S0140-6736(21)00448.
    PubMed    
    
    
    
93. SKEGG D, Gluckman P, Boulton G, Hackmann H, et al
    Future scenarios for the COVID-19 pandemic.
    Lancet. 2021 Feb 16. pii: S0140-6736(21)00424.
    PubMed    
    
    
    
94. MAKONI M
    Tanzania refuses COVID-19 vaccines.
    Lancet. 2021;397:566.
    PubMed    
    
    
    
95. THE LANCET
    Improving prisoner health for stronger public health.
    Lancet. 2021;397:555.
    PubMed    
    
    
    
96. WOUTERS OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, et al
    Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
    Lancet. 2021 Feb 12. pii: S0140-6736(21)00306.
    PubMed     Abstract available
    
    
    
97. 
    Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission.
    Lancet. 2021 Feb 12. pii: S0140-6736(21)00388.
    PubMed    
    
    
    
98. FONTANET A, Autran B, Lina B, Kieny MP, et al
    SARS-CoV-2 variants and ending the COVID-19 pandemic.
    Lancet. 2021 Feb 11. pii: S0140-6736(21)00370.
    PubMed    
    
    
    
99. MARTIN S, Arawi T
    Ensure Palestinians have access to COVID-19 vaccines.
    Lancet. 2021 Feb 9. pii: S0140-6736(21)00190.
    PubMed    
    
    
    
100. BEHRENS RH, Patel V
     Avoiding shoulder injury from intramuscular vaccines.
     Lancet. 2021;397:471.
     PubMed    
     
     
     
101. WARRELL MJ
     Time to revise the strategy for Gavi funding of rabies vaccine?
     Lancet. 2021;397:471-472.
     PubMed    
     
     
     
102. LANE R
     Tahmeed Ahmed: new leader of icddr,b.
     Lancet. 2021;397:463.
     PubMed    
     
     
     
103. LOIZIDES U, Adisa A, de la Rica Manjavacas AL, Robertson JS, et al
     WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.
     Lancet. 2021 Feb 4. pii: S0140-6736(21)00099.
     PubMed    
     
     
     
104. MEREWOOD A, Bode L, Davanzo R, Perez-Escamilla R, et al
     Breastfeed or be vaccinated-an unreasonable default recommendation.
     Lancet. 2021 Feb 4. pii: S0140-6736(21)00197.
     PubMed    
     
     
     
105. CLARFIELD AM, Skorecki K, Manor O, Glick S, et al
     A COVID-19 jab in the right direction.
     Lancet. 2021 Feb 4. pii: S0140-6736(21)00310.
     PubMed    
     
     
     
106. JONES I, Roy P
     Sputnik V COVID-19 vaccine candidate appears safe and effective.
     Lancet. 2021 Feb 2. pii: S0140-6736(21)00191.
     PubMed    
     
     
     
107. LOGUNOV DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, et al
     Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
     Lancet. 2021 Feb 2. pii: S0140-6736(21)00234.
     PubMed     Abstract available
     
     
     
108. FRIESEN P, Caplan AL, Miller JE
     COVID-19 vaccine research and the trouble with clinical equipoise.
     Lancet. 2021 Feb 1. pii: S0140-6736(21)00198.
     PubMed    
     
     
     January 2021
109. LI X, Mukandavire C, Cucunuba ZM, Echeverria Londono S, et al
     Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.
     Lancet. 2021;397:398-408.
     PubMed     Abstract available
     
     
     
110. DANIELS JP
     Health experts slam Bolsonaro's vaccine comments.
     Lancet. 2021;397:361.
     PubMed    
     
     
     
111. COHEN AL, Patel MK, Cherian T
     Vaccines work: a reason for celebration and renewed commitment.
     Lancet. 2021;397:351-353.
     PubMed    
     
     
     
112. THE LANCET
     Health and care workers are owed a better future.
     Lancet. 2021;397:347.
     PubMed    
     
     
     
113. BLAKNEY AK, McKay PF
     Next-generation COVID-19 vaccines: here come the proteins.
     Lancet. 2021 Jan 29. pii: S0140-6736(21)00258.
     PubMed    
     
     
     
114. RICHMOND P, Hatchuel L, Dong M, Ma B, et al
     Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
     Lancet. 2021 Jan 29. pii: S0140-6736(21)00241.
     PubMed     Abstract available
     
     
     
115. 
     Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.
     Lancet. 2021 Jan 28. pii: S0140-6736(21)00242.
     PubMed    
     
     
     
116. WATT G, Giacaman R, Zurayk H, Bjertness E, et al
     COVID-19 vaccines for Palestinians.
     Lancet. 2021 Jan 28. pii: S0140-6736(21)00185.
     PubMed    
     
     
     
117. BARDAJI A, Sevene E, Cutland C, Menendez C, et al
     The need for a global COVID-19 maternal immunisation research plan.
     Lancet. 2021 Jan 25. pii: S0140-6736(21)00146.
     PubMed    
     
     
     
118. BHUYAN A
     India begins COVID-19 vaccination amid trial allegations.
     Lancet. 2021;397:264.
     PubMed    
     
     
     
119. MAKONI M
     South Africa responds to new SARS-CoV-2 variant.
     Lancet. 2021;397:267.
     PubMed    
     
     
     
120. USHER AD
     CEPI criticised for lack of transparency.
     Lancet. 2021;397:265-266.
     PubMed    
     
     
     
121. CAVALERI M, Enzmann H, Straus S, Cooke E, et al
     The European Medicines Agency's EU conditional marketing authorisations for COVID-19 vaccines.
     Lancet. 2021 Jan 13. pii: S0140-6736(21)00085.
     PubMed    
     
     
     
122. STAPLES JE, Alvarez AR
     Public health role for fractional dosage of yellow fever vaccine.
     Lancet. 2021;397:76-77.
     PubMed    
     
     
     
123. JUAN-GINER A, Kimathi D, Grantz KH, Hamaluba M, et al
     Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.
     Lancet. 2021;397:119-127.
     PubMed     Abstract available
     
     
     
124. GOSTIN LO, Shalala DE, Hamburg MA, Bloom BR, et al
     A global health action agenda for the Biden administration.
     Lancet. 2021;397:5-8.
     PubMed    
     
     
     December 2020
125. HARMAN S, Herten-Crabb A, Morgan R, Smith J, et al
     COVID-19 vaccines and women's security.
     Lancet. 2020 Dec 22. pii: S0140-6736(20)32727.
     PubMed    
     
     
     
126. CLAESON M, Hanson S
     COVID-19 and the Swedish enigma.
     Lancet. 2020 Dec 22. pii: S0140-6736(20)32750.
     PubMed    
     
     
     
127. SIVA N
     Experts call to include prisons in COVID-19 vaccine plans.
     Lancet. 2020;396:1870.
     PubMed    
     
     
     
128. BURGESS RA, Osborne RH, Yongabi KA, Greenhalgh T, et al
     The COVID-19 vaccines rush: participatory community engagement matters more than ever.
     Lancet. 2020 Dec 10. pii: S0140-6736(20)32642.
     PubMed    
     
     
     
129. DE COSTER I, Leroux-Roels I, Bandyopadhyay AS, Gast C, et al
     Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
     Lancet. 2020 Dec 9. pii: S0140-6736(20)32541.
     PubMed     Abstract available
     
     
     
130. SAEZ-LLORENS X, Bandyopadhyay AS, Gast C, Leon T, et al
     Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials.
     Lancet. 2020 Dec 9. pii: S0140-6736(20)32540.
     PubMed     Abstract available
     
     
     
131. THOMPSON KM
     Poliovirus vaccine options: another step forward.
     Lancet. 2020 Dec 9. pii: S0140-6736(20)32629.
     PubMed    
     
     
     
132. ARYEETEY E, Engebretsen E, Gornitzka A, Maassen P, et al
     A step backwards in the fight against global vaccine inequities.
     Lancet. 2020 Dec 9. pii: S0140-6736(20)32596.
     PubMed    
     
     
     
133. KNOLL MD, Wonodi C
     Oxford-AstraZeneca COVID-19 vaccine efficacy.
     Lancet. 2020 Dec 8. pii: S0140-6736(20)32623.
     PubMed    
     
     
     
134. VOYSEY M, Clemens SAC, Madhi SA, Weckx LY, et al
     Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
     Lancet. 2020 Dec 8. pii: S0140-6736(20)32661.
     PubMed     Abstract available
     
     
     
135. USHER AD
     South Africa and India push for COVID-19 patents ban.
     Lancet. 2020;396:1790-1791.
     PubMed    
     
     
     
136. THE LANCET
     An African plan to control COVID-19 is urgently needed.
     Lancet. 2020;396:1777.
     PubMed    
     
     
     
137. MULHOLLAND K, Kretsinger K, Wondwossen L, Crowcroft N, et al
     Action needed now to prevent further increases in measles and measles deaths in the coming years.
     Lancet. 2020;396:1782-1784.
     PubMed    
     
     
     November 2020
138. THE LANCET
     COVID-19 vaccines: no time for complacency.
     Lancet. 2020;396:1607.
     PubMed    
     
     
     
139. RAMASAMY MN, Minassian AM, Ewer KJ, Flaxman AL, et al
     Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
     Lancet. 2020 Nov 18. pii: S0140-6736(20)32466.
     PubMed     Abstract available
     
     
     
140. ANDREW MK, McElhaney JE
     Age and frailty in COVID-19 vaccine development.
     Lancet. 2020 Nov 18. pii: S0140-6736(20)32481.
     PubMed    
     
     
     
141. VOYSEY M, Pollard AJ
     ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.
     Lancet. 2020;396:1486-1487.
     PubMed    
     
     
     
142. LODGE A
     ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
     Lancet. 2020;396:1486.
     PubMed    
     
     
     
143. CHAUHAN A, Agarwal A, Jaiswal N, Singh M, et al
     ChAdOx1 nCoV-19 vaccine for SARS-CoV-2.
     Lancet. 2020;396:1485-1486.
     PubMed    
     
     
     
144. HORTON R
     Offline: Managing the COVID-19 vaccine infodemic.
     Lancet. 2020;396:1474.
     PubMed    
     
     
     
145. SMITH MJ, Ujewe S, Katz R, Upshur REG, et al
     Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.
     Lancet. 2020 Nov 5. pii: S0140-6736(20)32337.
     PubMed    
     
     
     
146. ANDERSON RM, Vegvari C, Truscott J, Collyer BS, et al
     Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.
     Lancet. 2020 Nov 4. pii: S0140-6736(20)32318.
     PubMed    
     
     
     October 2020
147. HASSAN-SMITH Z, Hanif W, Khunti K
     Who should be prioritised for COVID-19 vaccines?
     Lancet. 2020 Oct 27. pii: S0140-6736(20)32224.
     PubMed    
     
     
     
148. BINGHAM K
     The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world.
     Lancet. 2020 Oct 27. pii: S0140-6736(20)32175.
     PubMed    
     
     
     
149. KRAUSE PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM, et al
     Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.
     Lancet. 2020 Oct 27. pii: S0140-6736(20)32259.
     PubMed    
     
     
     
150. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
     Use of adenovirus type-5 vectored vaccines: a cautionary tale.
     Lancet. 2020 Oct 19. pii: S0140-6736(20)32156.
     PubMed    
     
     
     
151. WARD BJ, Makarkov A, Seguin A, Pillet S, et al
     Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (>/=65 years): two multicentre, randomised phase 3 trials.
     Lancet. 2020 Oct 13. pii: S0140-6736(20)32014.
     PubMed     Abstract available
     
     
     
152. POLAND GA, Ovsyannikova IG, Kennedy RB
     SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.
     Lancet. 2020 Oct 13. pii: S0140-6736(20)32137.
     PubMed     Abstract available
     
     
     
153. TREGONING JS
     First human efficacy study of a plant-derived influenza vaccine.
     Lancet. 2020 Oct 13. pii: S0140-6736(20)32010.
     PubMed    
     
     
     
154. MCMAHON JH, Hoy JF, Kamarulzaman A, Bekker LG, et al
     Leveraging the advances in HIV for COVID-19.
     Lancet. 2020;396:943-944.
     PubMed    
     
     
     September 2020
155. LOGUNOV DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV, et al
     Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.
     Lancet. 2020 Sep 21. pii: S0140-6736(20)31970.
     PubMed    
     
     
     
156. PEIRIS M, Leung GM
     What can we expect from first-generation COVID-19 vaccines?
     Lancet. 2020 Sep 21. pii: S0140-6736(20)31976.
     PubMed    
     
     
     
157. BUCCI E, Andreev K, Bjorkman A, Calogero RA, et al
     Safety and efficacy of the Russian COVID-19 vaccine: more information needed.
     Lancet. 2020 Sep 21. pii: S0140-6736(20)31960.
     PubMed    
     
     
     
158. THE LANCET
     Global collaboration for health: rhetoric versus reality.
     Lancet. 2020;396:735.
     PubMed    
     
     
     
159. DE FIGUEIREDO A, Simas C, Karafillakis E, Paterson P, et al
     Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study.
     Lancet. 2020 Sep 10. pii: S0140-6736(20)31558.
     PubMed     Abstract available
     
     
     
160. DAS P
     Heidi Larson: shifting the conversation about vaccine confidence.
     Lancet. 2020 Sep 10. pii: S0140-6736(20)31612.
     PubMed    
     
     
     
161. SALMON DA, Dudley MZ
     It is time to get serious about vaccine confidence.
     Lancet. 2020 Sep 10. pii: S0140-6736(20)31603.
     PubMed    
     
     
     
162. PHELAN AL, Eccleston-Turner M, Rourke M, Maleche A, et al
     Legal agreements: barriers and enablers to global equitable COVID-19 vaccine access.
     Lancet. 2020 Sep 7. pii: S0140-6736(20)31873.
     PubMed    
     
     
     
163. LOGUNOV DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, et al
     Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
     Lancet. 2020 Sep 3. pii: S0140-6736(20)31866.
     PubMed     Abstract available
     
     
     
164. BAR-ZEEV N, Inglesby T
     COVID-19 vaccines: early success and remaining challenges.
     Lancet. 2020 Sep 3. pii: S0140-6736(20)31867.
     PubMed    
     
     
     August 2020
165. KRAUSE P, Fleming TR, Longini I, Henao-Restrepo AM, et al
     COVID-19 vaccine trials should seek worthwhile efficacy.
     Lancet. 2020 Aug 27. pii: S0140-6736(20)31821.
     PubMed    
     
     
     
166. DASHRAATH P, Nielsen-Saines K, Madhi SA, Baud D, et al
     COVID-19 vaccines and neglected pregnancy.
     Lancet. 2020 Aug 27. pii: S0140-6736(20)31822.
     PubMed    
     
     
     
167. AIYEGBUSI OL, Calvert MJ
     Patient-reported outcomes: central to the management of COVID-19.
     Lancet. 2020 Aug 10. pii: S0140-6736(20)31724.
     PubMed    
     
     
     July 2020
168. KARIM SA
     COVID-19 vaccine affordability and accessibility.
     Lancet. 2020;396:238.
     PubMed    
     
     
     
169. HORTON R
     Offline: Preparing for a vaccine against COVID-19.
     Lancet. 2020;396:226.
     PubMed    
     
     
     
170. BAR-ZEEV N, Moss WJ
     Encouraging results from phase 1/2 COVID-19 vaccine trials.
     Lancet. 2020 Jul 20. pii: S0140-6736(20)31611.
     PubMed    
     
     
     
171. ZHU FC, Guan XH, Li YH, Huang JY, et al
     Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
     Lancet. 2020 Jul 20. pii: S0140-6736(20)31605.
     PubMed     Abstract available
     
     
     
172. FOLEGATTI PM, Ewer KJ, Aley PK, Angus B, et al
     Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
     Lancet. 2020 Jul 20. pii: S0140-6736(20)31604.
     PubMed     Abstract available
     
     
     June 2020
173. THE LANCET
     Global governance for COVID-19 vaccines.
     Lancet. 2020;395:1883.
     PubMed    
     
     
     
174. USHER AD
     COVID-19 vaccines for all?
     Lancet. 2020;395:1822-1823.
     PubMed    
     
     
     
175. NUTTALL P
     Vaccinating against mosquitoes: anticipating the unexpected.
     Lancet. 2020 Jun 11. pii: S0140-6736(20)31319.
     PubMed    
     
     
     
176. MANNING JE, Oliveira F, Coutinho-Abreu IV, Herbert S, et al
     Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial.
     Lancet. 2020 Jun 11. pii: S0140-6736(20)31048.
     PubMed     Abstract available
     
     
     
177. MULLARD A
     COVID-19 vaccine development pipeline gears up.
     Lancet. 2020;395:1751-1752.
     PubMed    
     
     
     May 2020
178. LEE N, McGeer A
     The starting line for COVID-19 vaccine development.
     Lancet. 2020 May 28. pii: S0140-6736(20)31239.
     PubMed    
     
     
     
179. ZHU FC, Li YH, Guan XH, Hou LH, et al
     Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
     Lancet. 2020 May 22. pii: S0140-6736(20)31208.
     PubMed     Abstract available
     
     
     
180. WHITEHEAD CL, Walker SP
     Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.
     Lancet. 2020 May 13. pii: S0140-6736(20)31029.
     PubMed    
     
     
     
181. PHELAN AL
     COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges.
     Lancet. 2020 May 4. pii: S0140-6736(20)31034.
     PubMed    
     
     
     April 2020
182. CURTIS N, Sparrow A, Ghebreyesus TA, Netea MG, et al
     Considering BCG vaccination to reduce the impact of COVID-19.
     Lancet. 2020 Apr 30. pii: S0140-6736(20)31025.
     PubMed    
     
     
     
183. KEATING C
     The history of the RTS,S/AS01 malaria vaccine trial.
     Lancet. 2020;395:1336-1337.
     PubMed    
     
     
     
184. LANE R
     Sarah Gilbert: carving a path towards a COVID-19 vaccine.
     Lancet. 2020;395:1247.
     PubMed    
     
     
     
185. THE LANCET
     A new roadmap for meningitis.
     Lancet. 2020;395:1230.
     PubMed    
     
     
     
186. ALFARO-MURILLO JA, Avila-Aguero ML, Fitzpatrick MC, Crystal CJ, et al
     The case for replacing live oral polio vaccine with inactivated vaccine in the Americas.
     Lancet. 2020;395:1163-1166.
     PubMed    
     
     
     March 2020
187. YAMEY G, Schaferhoff M, Hatchett R, Pate M, et al
     Ensuring global access to COVID-19 vaccines.
     Lancet. 2020 Mar 31. pii: S0140-6736(20)30763.
     PubMed    
     
     
     
188. MEMISH ZA, Perlman S, Van Kerkhove MD, Zumla A, et al
     Middle East respiratory syndrome.
     Lancet. 2020;395:1063-1077.
     PubMed     Abstract available
     
     
     
189. TRICOU V, Saez-Llorens X, Yu D, Rivera L, et al
     Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
     Lancet. 2020 Mar 17. pii: S0140-6736(20)30556.
     PubMed     Abstract available
     
     
     
190. WILDER-SMITH A
     Evaluation of a tetravalent dengue vaccine by serostatus and serotype.
     Lancet. 2020 Mar 17. pii: S0140-6736(20)30603.
     PubMed    
     
     
     
191. BISWAL S, Borja-Tabora C, Martinez Vargas L, Velasquez H, et al
     Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial.
     Lancet. 2020 Mar 17. pii: S0140-6736(20)30414.
     PubMed     Abstract available
     
     
     
192. ZAROCOSTAS J
     Hope for the Ebola outbreak in DR Congo.
     Lancet. 2020;395:773.
     PubMed    
     
     
     February 2020
193. FIDLER S, Stohr W, Pace M, Dorrell L, et al
     Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial.
     Lancet. 2020 Feb 18. pii: S0140-6736(19)32990.
     PubMed     Abstract available
     
     
     
194. PHUMAPHI J, Gautam KC, Mason E
     Increased production and comprehensive guidelines needed for HPV vaccine.
     Lancet. 2020;395:319-321.
     PubMed    
     
     
     January 2020
195. BRISSON M, Kim JJ, Canfell K, Drolet M, et al
     Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
     Lancet. 2020 Jan 30. pii: S0140-6736(20)30068.
     PubMed     Abstract available
     
     
     
196. CANFELL K, Kim JJ, Brisson M, Keane A, et al
     Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
     Lancet. 2020 Jan 30. pii: S0140-6736(20)30157.
     PubMed     Abstract available
     
     
     
197. BROTONS M, Bruni L
     Population-level impact of human papillomavirus vaccination.
     Lancet. 2020 Jan 20. pii: S0140-6736(19)33153.
     PubMed    
     
     
     
198. SASIENI P, Cuzick J
     Population-level impact of human papillomavirus vaccination.
     Lancet. 2020 Jan 20. pii: S0140-6736(19)33109.
     PubMed    
     
     
     
199. DROLET M, Brisson M
     Population-level impact of human papillomavirus vaccination - Authors' reply.
     Lancet. 2020 Jan 20. pii: S0140-6736(19)33158.
     PubMed    
     
     
     
200. MIYACHI T, Takita M, Senoo Y, Yamamoto K, et al
     Lower trust in national government links to no history of vaccination.
     Lancet. 2020;395:31-32.
     PubMed    
     
     
     December 2019
201. WILDER-SMITH A, Flasche S, Smith PG
     Vaccine-attributable severe dengue in the Philippines.
     Lancet. 2019;394:2151-2152.
     PubMed    
     
     
     
202. HOLT E
     Global surge in measles should be "a wake-up call".
     Lancet. 2019;394:2137.
     PubMed    
     
     
     
203. BEKKER LG, Tatoud R, Dabis F, Feinberg M, et al
     The complex challenges of HIV vaccine development require renewed and expanded global commitment.
     Lancet. 2019 Dec 2. pii: S0140-6736(19)32682.
     PubMed    
     
     
     November 2019
204. BURKI T
     Ebola virus vaccine receives prequalification.
     Lancet. 2019;394:1893.
     PubMed    
     
     
     
205. SHUSTER S
     The life improvement value: a new measure of cost-efficiency.
     Lancet. 2019;394:1903-1904.
     PubMed    
     
     
     
206. MAKRI A
     Progress lags on vaccines to beat antimicrobial resistance.
     Lancet. 2019;394:1793-1794.
     PubMed    
     
     
     October 2019
207. THORNTON J
     Polio returns to the Philippines.
     Lancet. 2019;394:1217.
     PubMed    
     
     
     September 2019
208. ALI M, Ahmad N, Khan H, Ali S, et al
     Polio vaccination controversy in Pakistan.
     Lancet. 2019;394:915-916.
     PubMed    
     
     
     
209. REUTER A, Hughes J, Furin J
     Challenges and controversies in childhood tuberculosis.
     Lancet. 2019;394:967-978.
     PubMed     Abstract available
     
     
     August 2019
210. LOH LC
     Mandatory reporting and vaccination in North America.
     Lancet. 2019 Aug 13. pii: S0140-6736(19)31253.
     PubMed    
     
     
     July 2019
211. ZAROCOSTAS J
     Ebola outbreak declared a PHEIC, world waits for next steps.
     Lancet. 2019;394:287-288.
     PubMed    
     
     
     
212. ADEPOJU P
     The yellow fever vaccination certificate loophole in Nigeria.
     Lancet. 2019;394:203-204.
     PubMed    
     
     
     
213. SCHUERMAN L
     RTS,S malaria vaccine could provide major public health benefits.
     Lancet. 2019 Jul 9. pii: S0140-6736(19)31567.
     PubMed    
     
     
     
214. NAKKAZI E
     Apply to trial Ebola vaccines in DR Congo, says ministry.
     Lancet. 2019;394:15-16.
     PubMed    
     
     
     June 2019
215. DROLET M, Benard E, Perez N, Brisson M, et al
     Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
     Lancet. 2019 Jun 26. pii: S0140-6736(19)30298.
     PubMed     Abstract available
     
     
     
216. DE SANJOSE S, Delany-Moretlwe S
     HPV vaccines can be the hallmark of cancer prevention.
     Lancet. 2019 Jun 26. pii: S0140-6736(19)30549.
     PubMed    
     
     
     
217. MORI Y, Katasako A, Matsunaga S, Matono T, et al
     Tetanus: remember to vaccinate.
     Lancet. 2019;393:2331.
     PubMed    
     
     
     
218. THOMPSON KM
     Polio endgame options: will we have the vaccines needed?
     Lancet. 2019 Jun 4. pii: S0140-6736(19)31294.
     PubMed    
     
     
     
219. VAN DAMME P, De Coster I, Bandyopadhyay AS, Revets H, et al
     The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
     Lancet. 2019 Jun 4. pii: S0140-6736(19)31279.
     PubMed     Abstract available
     
     
     May 2019
220. THE LANCET
     Acknowledging the limits of public health solutions.
     Lancet. 2019;393:2100.
     PubMed    
     
     
     
221. USHER AD
     Low-cost pneumonia vaccine breaks into global market.
     Lancet. 2019;393:2025-2026.
     PubMed    
     
     
     
222. ROBERT A, Funk S, Kucharski AJ
     The measles crisis in Europe-the need for a joined-up approach.
     Lancet. 2019;393:2033.
     PubMed    
     
     
     
223. SNIDER CJ, Zaman K, Estivariz CF, Yunus M, et al
     Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
     Lancet. 2019 May 16. pii: S0140-6736(19)30503.
     PubMed     Abstract available
     
     
     
224. SUTTER RW, Zaffran M
     Addressing the inactivated poliovirus vaccine shortage.
     Lancet. 2019 May 16. pii: S0140-6736(19)30766.
     PubMed    
     
     
     
225. DE FIGUEIREDO A, Were F
     Local trends in immunisation coverage across Africa.
     Lancet. 2019;393:1779-1781.
     PubMed    
     
     
     April 2019
226. ADEPOJU P
     RTS,S malaria vaccine pilots in three African countries.
     Lancet. 2019;393:1685.
     PubMed    
     
     
     
227. HAMMITT LL, Etyang AO, Morpeth SC, Ojal J, et al
     Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.
     Lancet. 2019 Apr 15. pii: S0140-6736(18)33005.
     PubMed     Abstract available
     
     
     
228. KLUGMAN KP, Rodgers GL
     Population versus individual protection by pneumococcal conjugate vaccination.
     Lancet. 2019 Apr 15. pii: S0140-6736(19)30039.
     PubMed    
     
     
     
229. MOSSER JF, Gagne-Maynard W, Rao PC, Osgood-Zimmerman A, et al
     Mapping diphtheria-pertussis-tetanus vaccine coverage in Africa, 2000-2016: a spatial and temporal modelling study.
     Lancet. 2019 Apr 5. pii: S0140-6736(19)30226.
     PubMed     Abstract available
     
     
     March 2019
230. NAYAR RK, Nair AT, Shaffi M, Swarnam K, et al
     Methods to overcome vaccine hesitancy.
     Lancet. 2019;393:1203-1204.
     PubMed    
     
     
     
231. THE LANCET
     Canada's mandatory vaccination reporting plans.
     Lancet. 2019;393:960.
     PubMed    
     
     
     
232. ZHAO F, Qiao Y
     Cervical cancer prevention in China: a key to cancer control.
     Lancet. 2019;393:969-970.
     PubMed    
     
     
     
233. MALVY D, McElroy AK, de Clerck H, Gunther S, et al
     Ebola virus disease.
     Lancet. 2019;393:936-948.
     PubMed     Abstract available
     
     
     
234. GAUDINSKI MR, Coates EE, Novik L, Widge A, et al
     Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
     Lancet. 2019;393:889-898.
     PubMed     Abstract available
     
     
     February 2019
235. GOSTIN L, Phelan A, Coutinho AG, Eccleston-Turner M, et al
     Ebola in the Democratic Republic of the Congo: time to sound a global alert?
     Lancet. 2019 Feb 1. pii: S0140-6736(19)30243.
     PubMed    
     
     
     January 2019
236. WILDER-SMITH A, Ooi EE, Horstick O, Wills B, et al
     Dengue.
     Lancet. 2019;393:350-363.
     PubMed     Abstract available
     
     
     
237. COHEN PA, Jhingran A, Oaknin A, Denny L, et al
     Cervical cancer.
     Lancet. 2019;393:169-182.
     PubMed     Abstract available
     
     
     
238. THE LANCET
     Cervical cancer: unequal progress.
     Lancet. 2019;393:104.
     PubMed    
     
     
     
239. SHUCHMAN M
     Logistical challenges in the DR Congo Ebola virus response.
     Lancet. 2019;393:117-118.
     PubMed    
     
     
     November 2018
240. LARSON HJ
     The state of vaccine confidence.
     Lancet. 2018;392:2244-2246.
     PubMed    
     
     
     
241. THE LANCET
     Looking beyond the Decade of Vaccines.
     Lancet. 2018;392:2139.
     PubMed    
     
     
     
242. CHANDLER J
     Fighting a polio outbreak in Papua New Guinea.
     Lancet. 2018;392:2155-2156.
     PubMed    
     
     
     
243. POWERS AM
     Licensed chikungunya virus vaccine: a possibility?
     Lancet. 2018 Nov 5. pii: S0140-6736(18)32809.
     PubMed    
     
     
     
244. REISINGER EC, Tschismarov R, Beubler E, Wiedermann U, et al
     Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
     Lancet. 2018 Nov 5. pii: S0140-6736(18)32488.
     PubMed     Abstract available
     
     
     October 2018
245. CLAUDE KM, Underschultz J, Hawkes MT
     Ebola virus epidemic in war-torn eastern DR Congo.
     Lancet. 2018;392:1399-1401.
     PubMed    
     
     
     
246. MARKS F, Kim JH, Rakotozandrindrainy R
     Madagascar should introduce typhoid conjugate vaccines now.
     Lancet. 2018;392:1309-1310.
     PubMed    
     
     
     September 2018
247. ZIMMER BL, Gamble L, Mayer D, Foster R, et al
     Canine rabies vaccination reduces child rabies cases in Malawi.
     Lancet. 2018;392:1115-1116.
     PubMed    
     
     
     
248. PRUE G, Baker P, Graham D, Nutting C, et al
     It is time for universal HPV vaccination.
     Lancet. 2018;392:913-914.
     PubMed    
     
     
     
249. BURKI T
     Cochrane review methods called into question.
     Lancet. 2018;392:906.
     PubMed    
     
     
     
250. HOLT E
     41 000 measles cases in Europe since the beginning of 2018.
     Lancet. 2018;392:724.
     PubMed    
     
     
     August 2018
251. HAYFLICK L
     Subject of The Vaccine Race offers perspective on errors.
     Lancet. 2018;392:633-634.
     PubMed    
     
     
     
252. LEVY Y, Lane C, Piot P, Beavogui AH, et al
     Prevention of Ebola virus disease through vaccination: where we are in 2018.
     Lancet. 2018 Aug 10. pii: S0140-6736(18)31710.
     PubMed    
     
     
     
253. THE LANCET
     Vaccine scandal and confidence crisis in China.
     Lancet. 2018;392:360.
     PubMed    
     
     
     
254. GREEN A
     HPV vaccine to be offered to boys in England.
     Lancet. 2018;392:374.
     PubMed    
     
     
     
255. YUAN X
     China's vaccine production scare.
     Lancet. 2018;392:371.
     PubMed    
     
     
     
256. FRASER B
     Measles outbreak in the Americas.
     Lancet. 2018;392:373.
     PubMed    
     
     
     July 2018
257. BAROUCH DH, Tomaka FL, Wegmann F, Stieh DJ, et al
     Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
     Lancet. 2018;392:232-243.
     PubMed     Abstract available
     
     
     
258. PAVLAKIS GN, Felber BK
     A new step towards an HIV/AIDS vaccine.
     Lancet. 2018;392:192-194.
     PubMed    
     
     
     
259. LEWNARD JA
     Ebola virus disease: 11 323 deaths later, how far have we come?
     Lancet. 2018;392:189-190.
     PubMed    
     
     
     
260. DEVI S
     Setbacks in the fight to eradicate polio.
     Lancet. 2018;392:201-202.
     PubMed    
     
     
     
261. BANYAI K, Estes MK, Martella V, Parashar UD, et al
     Viral gastroenteritis.
     Lancet. 2018;392:175-186.
     PubMed     Abstract available
     
     
     June 2018
262. GREEN A
     DR Congo: investigational research against Ebola virus.
     Lancet. 2018;391:2308-2309.
     PubMed    
     
     
     May 2018
263. WINSTON DJ, Mullane KM, Cornely OA, Boeckh MJ, et al
     Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial.
     Lancet. 2018;391:2116-2127.
     PubMed     Abstract available
     
     
     
264. CORCORAN B, Clarke A, Barrett T
     Rapid response to HPV vaccination crisis in Ireland.
     Lancet. 2018;391:2103.
     PubMed    
     
     
     
265. MACARTNEY K, Gershon AA
     Shingles vaccine after auto-HSCT decreases risk.
     Lancet. 2018;391:2082-2084.
     PubMed    
     
     
     
266. KELLY JD, Mukadi P, Dhillon RS
     Beyond vaccines: improving survival rates in the DRC Ebola outbreak.
     Lancet. 2018 May 25. pii: S0140-6736(18)31212.
     PubMed    
     
     
     
267. QADRI F, Azad AK, Flora MS, Khan AI, et al
     Emergency deployment of oral cholera vaccine for the Rohingya in Bangladesh.
     Lancet. 2018;391:1877-1879.
     PubMed    
     
     
     
268. AGUIAR M
     Dengue vaccination: a more ethical approach is needed.
     Lancet. 2018;391:1769-1770.
     PubMed    
     
     
     
269. HARGREAVES S, Nellums LB, Ramsay M, Saliba V, et al
     Who is responsible for the vaccination of migrants in Europe?
     Lancet. 2018;391:1752-1754.
     PubMed    
     
     
     April 2018
270. THE LANCET
     Addressing decreasing vaccine coverage in the EU.
     Lancet. 2018;391:1638.
     PubMed    
     
     
     
271. CHEN S, Li J, Wang D, Fung H, et al
     The hepatitis B epidemic in China should receive more attention.
     Lancet. 2018;391:1572.
     PubMed    
     
     
     March 2018
272. PENG X, Hu X, Salazar MA
     On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine.
     Lancet. 2018 Mar 28. pii: S0140-6736(18)30483.
     PubMed    
     
     
     
273. WATTS G
     New York Challenge sets high bar for HPV vaccination.
     Lancet. 2018;391:1137.
     PubMed    
     
     
     
274. METZGER WG, Vivas-Martinez S
     Questionable efficacy of the rVSV-ZEBOV Ebola vaccine.
     Lancet. 2018;391:1021.
     PubMed    
     
     
     
275. LONGINI IM, Rottingen JA, Kieny MP, Edmunds WJ, et al
     Questionable efficacy of the rVSV-ZEBOV Ebola vaccine - Authors' reply.
     Lancet. 2018;391:1021-1022.
     PubMed    
     
     
     February 2018
276. PANG T, Gubler D, Goh DYT, Ismail Z, et al
     Dengue vaccination: a more balanced approach is needed.
     Lancet. 2018;391:654.
     PubMed    
     
     
     
277. LARSON HJ
     A global girl gang.
     Lancet. 2018;391:527-528.
     PubMed    
     
     
     
278. PAULES CI, Subbarao K
     Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.
     Lancet. 2018;391:427-428.
     PubMed    
     
     
     
279. CALDEIRA D, Ferreira JJ, Costa J
     Influenza vaccination and prevention of cardiovascular disease mortality.
     Lancet. 2018;391:426-427.
     PubMed    
     
     
     
280. THE LANCET
     Yellow fever: a major threat to public health.
     Lancet. 2018;391:402.
     PubMed    
     
     
     January 2018
281. THE LANCET
     Preparing for seasonal influenza.
     Lancet. 2018;391:180.
     PubMed    
     
     
     
282. THE LANCET
     A new vaccine for typhoid control.
     Lancet. 2018;391:96.
     PubMed    
     
     
     
283. PETOUSIS-HARRIS H, Paynter J, Morgan J, Saxton P, et al
     Pitfalls of the healthy vaccinee effect - Authors' reply.
     Lancet. 2018;391:123-124.
     PubMed    
     
     
     
284. MAHMUD SM, Righolt CH
     Pitfalls of the healthy vaccinee effect.
     Lancet. 2018;391:123.
     PubMed    
     
     
     
285. ZAFFRAN M, McGovern M, Hossaini R, Martin R, et al
     The polio endgame: securing a world free of all polioviruses.
     Lancet. 2018;391:11-13.
     PubMed    
     
     
     December 2017
286. MARQUES ETA, Burke DS
     Tradition and innovation in development of a Zika vaccine.
     Lancet. 2017 Dec 4. pii: S0140-6736(17)33107.
     PubMed    
     
     
     
287. GAUDINSKI MR, Houser KV, Morabito KM, Hu Z, et al
     Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
     Lancet. 2017 Dec 4. pii: S0140-6736(17)33105.
     PubMed     Abstract available
     
     
     
288. MODJARRAD K, Lin L, George SL, Stephenson KE, et al
     Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.
     Lancet. 2017 Dec 4. pii: S0140-6736(17)33106.
     PubMed     Abstract available
     
     
     October 2017
289. YIN Y
     HPV vaccination in China needs to be more cost-effective.
     Lancet. 2017;390:1735-1736.
     PubMed    
     
     
     September 2017
290. JIN C, Gibani MM, Moore M, Juel HB, et al
     Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
     Lancet. 2017 Sep 28. pii: S0140-6736(17)32149.
     PubMed     Abstract available
     
     
     
291. FEASEY NA, Levine MM
     Typhoid vaccine development with a human challenge model.
     Lancet. 2017 Sep 28. pii: S0140-6736(17)32407.
     PubMed    
     
     
     
292. HUH WK, Joura EA, Giuliano AR, Iversen OE, et al
     Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
     Lancet. 2017 Sep 5. pii: S0140-6736(17)31821.
     PubMed     Abstract available
     
     
     
293. DENNY L
     Nine-valent human papillomavirus vaccine: great science, but will it save lives?
     Lancet. 2017 Sep 5. pii: S0140-6736(17)32144.
     PubMed    
     
     
     November 2016
294. DENNY L, de Sanjose S, Mutebi M, Anderson BO, et al
     Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries.
     Lancet. 2016 Nov 1. pii: S0140-6736(16)31795.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: